Abstract
Angiotensin converting enzyme (ACE) inhibitors reduce morbidity and mortality in patients with heart failure and are a first-line therapy for chronic heart failure. However, the first-dose may be associated with asymptomatic or symptomatic hypotension. In previous small series with different ACE inhibitors, different blood pressure responses have been reported. We defined hypotension as a fall in mean blood pressure ≥20 mm Hg and an absolute value of systolic blood pressure ≤90 mm Hg and diastolic blood pressure ≤60 mm Hg. We studied the evolution of mean, systolic and diastolic blood pressure after initiation of perindopril and captopril treatments in a multicentre, double-blind, randomised, comparative, prospective study. One hundred seventy-six patients, mean age 64.9 ± 12.1 years, 116 men, with symptomatic heart failure, NYHA class II–IV, and a left ventricular ejection fraction <40%, were randomised to receive a single dose of captopril 6.25 mg (n = 85) or perindopril 2 mg, (n = 91). Systolic and diastolic blood pressure were recorded with Dinamap every 15 minutes during a baseline period of 2 hours, every 30 minutes from 2 to 7 hours and at 8 hours after the drug administration. Baseline characteristics of both groups were similar (demography, heart failure aetiology, NYHA class and blood pressure). Throughout the study there were 23 asymptomatic episodes of hypotension in the captopril group and 6 in the perindopril group (p = 0.039). One patient in the captopril group had symptomatic episodes.
Mean blood pressure falls were significantly higher in the captopril versus perindopril group at 60 minutes (−4.6 mm Hg vs +0.7 mm Hg; p = 0.004), 75 minutes (−4.4 mm Hg vs −1.1 mm Hg; p = 0.042), and 180 minutes (−3.4 mm Hg vs +0.0 mm Hg; p = 0.042).
When elderly patients (≥70 years) were considered the same pattern of response was found. In summary, first-dose hypotension is not negligible on initiation of therapy with ACE inhibitors in heart failure patients with low ejection fraction. Perindopril results in significantly less reduction in blood pressure and a lower incidence of symptomatic or asymptomatic hypotensive episodes and allows a safer start of therapy than captopril in heart failure patients.
Similar content being viewed by others
References
The Task Force on Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis of heart failure. Eur Heart J 1995; 16: 741-751.
ACC/AHA Task Force Report: Guidelines for the evaluation and management of heart failure. J Am Coll Cardiol 1995; 26: 1376-1398.
Cleland JGF, Dargie HG, MC Alpine H, et al. Severe hypotension after first dose of enalapril in heart failure. Br Med J 1995; 291: 1309-1312.
Packer M, Hung Lee W, Yushak M, Medina N. Comparison of captopril and enalapril in patients in severe chronic heart failure. N Engl J Med 1986; 315: 847-853.
Squire IB, MacFadyen RJ, Reid JL, Devlin A, Lees KR. Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure. J Cardiovasc Pharmacol 1996; 27: 657-666.
Reid J. Differing blood pressure and renin-angiotensin responses to angiotensin-converting enzyme inhibitors in heart failure: An overview. Clin Cardiol 1996; 19( Suppl I, Intn'l), I-16-I-18.
Navookarasu NT, Rahman ARA, Abdullah I. First dose response to angiotensin-converting enzyme inhibition in congestive cardiac failure: A malaysian experience. Int J Clin Pract 1999; 53: 25-30.
Lau C, Tse HF, NG W, et al. Are different angiotensin converting enzyme inhibitors identical for treatment of acute myocardial infarction? Results from the Hong-Kong postmyocardial infarction trial. Eur Heart J 1999; 20: Abst Suppl 287.
Swedberg K, Held P, Kjekshus, et al. On behalf of the CONSENSUS II Study Group. Effects of early administration of enalapril on mortality in patients with acute myocardial infarction: Results of the Cooperative North Scandinavian Enalapril Survival Study II (CONSENSUS II). N Eng J Med 1992; 327: 678-684.
Chinese Cardiac Study collaborative group. Oral captopril vs placebo among 13634 patients with suspected acute myocardial infarction: Interim report from the Chinese cardiac study (CCSI). Lancet 1995; 345: 686-687.
ISIS 4 (Fourth International Study of Infarct Survival) collaborative Group. ISIS 4:Arandomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulfate in 58050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-685.
The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Eng J Med 1991; 325: 293-302.
Latini R, Maggioni AP, Flather M, et al. ACE inhibitor use in patients with myocardial infarction: Summary evidence from clinical trials. Circulation 1995; 92: 3132-3137.
Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI 3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-1122.
Reid JL, McFadyen RJ, Squire IB. Angiotensin converting enzyme inhibition in heart failure: Blood pressure changes after the first dose. Am Heart J 1993; 126: 794-797.
Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993; 153: 837-842.
Zhuo JL, Froomes P, Casley D, et al. Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease. Circulation 1997; 96: 174-182.
Author information
Consortia
Rights and permissions
About this article
Cite this article
Portuguese Community Hospital Study Group on Heart Failure. A Comparative Study of the First Dose Hypotensive Effects of Captopril and Perindopril in Patients with Heart Failure. Cardiovasc Drugs Ther 15, 501–506 (2001). https://doi.org/10.1023/A:1013763603926
Issue Date:
DOI: https://doi.org/10.1023/A:1013763603926